Evidence supports the use of mammalian target of rapamycin (mTOR)-inhibitors as adjunctive treatment to AEDs for treating focal epilepsy in TSC individuals, with a higher response rate in the younger subgroup aged below 6 years (11–13). Here, MTOR is linked to tuberous sclerosis.